News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,575 Results
Type
Article (39049)
Company Profile (279)
Press Release (646247)
Section
Business (203866)
Career Advice (1990)
Deals (35364)
Drug Delivery (85)
Drug Development (80799)
Employer Resources (168)
FDA (16086)
Job Trends (14804)
News (344543)
Policy (32436)
Tag
Academia (2530)
Alliances (49087)
Alzheimer's disease (1228)
Approvals (16018)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11534)
Biotechnology (200)
Breast cancer (120)
Cancer (1081)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (232)
Clinical research (64240)
Collaboration (387)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84817)
Employer resources (146)
Events (109470)
Executive appointments (310)
FDA (16621)
Funding (349)
Gene therapy (177)
GLP-1 (575)
Government (4324)
Healthcare (18668)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16297)
Job creations (3623)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19142)
Metabolic disorders (401)
Neuroscience (1503)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1476)
Obesity (231)
Opinion (179)
Patents (102)
People (56269)
Phase I (19951)
Phase II (28299)
Phase III (21095)
Pipeline (455)
Postmarket research (2553)
Preclinical (8492)
Radiopharmaceuticals (236)
Rare diseases (218)
Real estate (5890)
Regulatory (21517)
Research institute (2308)
Resumes & cover letters (349)
Southern California (1298)
Startups (3562)
United States (13445)
Vaccines (548)
Weight loss (167)
Date
Today (129)
Last 7 days (802)
Last 30 days (3795)
Last 365 days (35626)
2024 (32673)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31482)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29265)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37118)
Australia (6057)
California (3318)
Canada (1286)
China (247)
Colorado (144)
Connecticut (152)
Europe (79501)
Florida (458)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2602)
Michigan (157)
Minnesota (272)
New Jersey (952)
New York (957)
North Carolina (701)
Northern California (1476)
Ohio (139)
Pennsylvania (843)
South America (1091)
Southern California (1298)
Texas (461)
Utah (90)
Washington State (360)
685,575 Results for "axogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
Axogen, Inc. announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing.
June 24, 2024
·
6 min read
Press Releases
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
November 7, 2024
·
15 min read
BioMidwest
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
Axogen, Inc. will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference in Austin, TX, on Wednesday, May 29, 2024, at 3:40 p.m. CT / 4:40 p.m. ET.
May 14, 2024
·
3 min read
Business
Axogen, Inc Reports First Quarter 2024 Financial Results
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the first quarter ended March 31, 2024.
May 2, 2024
·
19 min read
Press Releases
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
October 25, 2024
·
3 min read
BioMidwest
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it will celebrate the opening of its Axogen Processing Center with leaders of the Ohio community on June 12, 2024.
May 28, 2024
·
6 min read
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
Axogen, Inc. is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft ® on May 15, 2024.
May 16, 2024
·
7 min read
Press Releases
Axogen, Inc. Announces New Leadership Appointments
August 9, 2024
·
6 min read
Business
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens.
April 16, 2024
·
3 min read
Business
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
March 5, 2024
·
17 min read
1 of 68,558
Next
